TG Therapeutics (NASDAQ:TGTX) Stock Price Up 3.4%

TG Therapeutics, Inc. (NASDAQ:TGTX) shares rose 3.4% on Thursday . The company traded as high as $18.35 and last traded at $18.33. Approximately 170,370 shares were traded during trading, a decline of 96% from the average daily volume of 3,819,496 shares. The stock had previously closed at $17.73.

Analyst Upgrades and Downgrades

TGTX has been the topic of a number of research reports. LADENBURG THALM/SH SH lifted their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a report on Thursday, April 18th. Finally, HC Wainwright lifted their target price on shares of TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.83.

TG Therapeutics Trading Down 0.9 %

The firm has a market capitalization of $2.75 billion, a P/E ratio of 77.35 and a beta of 2.30. The stock’s 50-day simple moving average is $16.45 and its two-hundred day simple moving average is $16.08. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.62 and a quick ratio of 2.84.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $63.47 million during the quarter, compared to the consensus estimate of $54.60 million. TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The business’s revenue for the quarter was up 713.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.28) earnings per share. Equities research analysts expect that TG Therapeutics, Inc. will post -0.01 EPS for the current year.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TGTX. Pingora Partners LLC bought a new position in shares of TG Therapeutics during the fourth quarter worth $27,000. PNC Financial Services Group Inc. boosted its position in shares of TG Therapeutics by 131.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,014 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of TG Therapeutics during the first quarter worth $58,000. Anchor Investment Management LLC bought a new position in shares of TG Therapeutics during the fourth quarter worth $80,000. Finally, Lazard Asset Management LLC bought a new position in shares of TG Therapeutics during the first quarter worth $91,000. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.